Skip to main content

Table 8 One-way sensitivity analysis results for genotype 2/3 comparing peginterferon-alfa-2a to peginterferon-alfa-2b

From: Cost-effectiveness analysis of treatment with peginterferon-alfa-2a versus peginterferon-alfa-2b for patients with chronic hepatitis C under the public payer perspective in Brazil

Parameter

Lower parameter value

Higher parameter value

Result

Cost difference

LY difference

QALY difference

Cost difference

LY difference

QALY difference

Utility values1

-$Brz 4345

0,10

0,34

-$Brz 4345

0,10

0,17

Dominant

Medical costs1

-$Brz 4098

0,10

0,26

-$Brz 4592

0,10

0,26

Dominant

State-transition probabilities1

-$Brz 4250

0,08

0,22

-$Brz 4411

0,13

0,27

Dominant

Peginterferon-alfa-2a acquisition cost1

-$Brz 5314

0,10

0,26

-$Brz 3376

0,10

0,26

Dominant

Peginterferon-alfa-2b acquisition cost1

-$Brz 2972

0,10

0,26

-$Brz 5718

0,10

0,26

Dominant

Patient weight2

-$Brz 1729

0,10

0,26

-$Brz 6961

0,10

0,26

Dominant

SVR3

-$Brz 3576

0,05

0,14

-$Brz 5114

0,15

0,38

Dominant

Starting age4

-$Brz 4459

0,13

0,29

-$Brz 4927

0,09

0,22

Dominant

  1. Notes: 1Parameters were varied over the range of ±15%; 2Parameter was varied from 50 to 90 kg; 3Parameter was varied according to lower and upper limit values obtained from meta-analysis; 4Parameter was varied from 40 to 50 years old.